[go: up one dir, main page]

PE20110394A1 - Virus sincitial respiratorio vivo atenuado - Google Patents

Virus sincitial respiratorio vivo atenuado

Info

Publication number
PE20110394A1
PE20110394A1 PE2011000971A PE2011000971A PE20110394A1 PE 20110394 A1 PE20110394 A1 PE 20110394A1 PE 2011000971 A PE2011000971 A PE 2011000971A PE 2011000971 A PE2011000971 A PE 2011000971A PE 20110394 A1 PE20110394 A1 PE 20110394A1
Authority
PE
Peru
Prior art keywords
protein coded
gen
gene
protein
glutamic acid
Prior art date
Application number
PE2011000971A
Other languages
English (en)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20110394A1 publication Critical patent/PE20110394A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN VIRUS SINCITIAL RESPIRATORIO VIVO ATENUADO (VSR) QUE COMPRENDE UN GENOMA VIRAL QUE CODIFICA PROTEINAS QUE COMPRENDEN UNO O MAS AMINOACIDOS TALES COMO: UN ACIDO GLUTAMICO EN LA POSICION 204 DE LA PROTEINA CODIFICADA POR EL GEN G, UN ACIDO GLUTAMICO EN LA POSICION 205 DE LA PROTEINA CODIFICADA POR EL GEN G, UNA ALANINA EN LA POSICION 211 DE LA PROTEINA CODIFICADA POR EL GEN G, UN ACIDO GLUTAMICO EN LA POSICION 213 DE LA PROTEINA CODIFICADA POR EL GEN G, UNA GLICINA EN LA POSICION 221 DE LA PROTEINA CODIFICADA POR EL GEN G, UN ACIDO GLUTAMICO EN LA POSICION 223 DE LA PROTEINA CODIFICADA POR EL GEN G, UNA GLICINA EN LA POSICION 232 DE LA PROTEINA CODIFICADA POR EL GEN G, UNA LISINA EN LA POSICION 294 DE LA PROTEINA CODIFICADA POR EL GEN F, UNA GLICINA EN LA POSICION 486 DE LA PROTEINA CODIFICADA POR EL GEN F, UNA ALANINA EN LA POSICION 148 DE LA PROTEINA CODIFICADA POR EL GEN L Y UNA FENILALANINA EN LA POSICION 2054 DE LA PROTEINA CODIFICADA POR EL GEN L. TAMBIEN ESTA REFERIDA A UNA MOLECULA DE ACIDO NUCLEICO, UNA CELULA RECOMBINANTE Y A UNA COMPOSICION INMUNOGENICA. DICHOS VIRUS ATENUADOS SON UTILES COMO VACUNAS CONTRA INFECCIONES POR VSR Y/O ENFERMEDADES ASOCIADAS AL MISMO
PE2011000971A 2008-11-05 2009-11-03 Virus sincitial respiratorio vivo atenuado PE20110394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
PE20110394A1 true PE20110394A1 (es) 2011-06-22

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000971A PE20110394A1 (es) 2008-11-05 2009-11-03 Virus sincitial respiratorio vivo atenuado

Country Status (19)

Country Link
US (1) US9011876B2 (es)
EP (1) EP2346990B1 (es)
JP (2) JP5016731B2 (es)
KR (1) KR20110063863A (es)
CN (1) CN102272295A (es)
AU (1) AU2009311287C1 (es)
BR (1) BRPI0921424A2 (es)
CA (1) CA2742086A1 (es)
CL (1) CL2011000999A1 (es)
CO (1) CO6362047A2 (es)
EC (1) ECSP11011033A (es)
IL (1) IL212437A0 (es)
MA (1) MA32878B1 (es)
MX (1) MX2011004719A (es)
PE (1) PE20110394A1 (es)
RU (1) RU2011122615A (es)
TN (1) TN2011000182A1 (es)
WO (1) WO2010053883A1 (es)
ZA (1) ZA201103259B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346990B1 (en) * 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
EP2744894A4 (en) * 2011-08-18 2015-04-22 Ycine Llc PRODUCTION OF INFECTIOUS RNA VIRUSES IN YEAST
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
PL2954049T3 (pl) * 2013-02-08 2023-10-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu
PL2970981T3 (pl) 2013-03-14 2021-07-05 Emory University Rekombinowany RSV z cichymi mutacjami, szczepionki i związane z nimi sposoby
EP3057611A4 (en) 2013-10-16 2017-04-12 Merck Sharp & Dohme Corp. Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2015057540A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
WO2017030997A1 (en) * 2015-08-14 2017-02-23 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered ns1 protein function and related materials and methods
JP7311872B2 (ja) 2015-10-29 2023-07-20 エモリー ユニバーシティー キメラｒｓｖ、免疫原性組成物、及び使用方法
JP7198759B2 (ja) 2016-09-23 2023-01-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN111344008A (zh) * 2017-09-15 2020-06-26 俄亥俄州创新基金会 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法
WO2025106787A1 (en) * 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Trehalose vaccine formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250883A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
JP2002507408A (ja) 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
WO2001004335A2 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Human-bovine chimeric respiratory syncytial virus vaccines
AU2003295339B2 (en) 2002-09-27 2009-03-26 Medimmune, Llc Functional mutations in respiratory syncytial virus
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2008096811A1 (ja) * 2007-02-07 2008-08-14 Dnavec Corporation 弱毒化マイナス鎖rnaウイルス
EP2346990B1 (en) * 2008-11-05 2016-01-06 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus

Also Published As

Publication number Publication date
ZA201103259B (en) 2012-01-25
KR20110063863A (ko) 2011-06-14
AU2009311287C1 (en) 2015-02-19
CA2742086A1 (en) 2010-05-14
EP2346990B1 (en) 2016-01-06
ECSP11011033A (es) 2011-12-30
IL212437A0 (en) 2011-06-30
JP2012507302A (ja) 2012-03-29
TN2011000182A1 (en) 2012-12-17
CL2011000999A1 (es) 2012-07-20
MA32878B1 (fr) 2011-12-01
AU2009311287A1 (en) 2010-05-14
EP2346990A1 (en) 2011-07-27
US20110212130A1 (en) 2011-09-01
US9011876B2 (en) 2015-04-21
CO6362047A2 (es) 2012-01-20
CN102272295A (zh) 2011-12-07
JP5743794B2 (ja) 2015-07-01
AU2009311287B2 (en) 2013-02-07
JP5016731B2 (ja) 2012-09-05
MX2011004719A (es) 2011-05-31
WO2010053883A1 (en) 2010-05-14
RU2011122615A (ru) 2012-12-20
JP2011250798A (ja) 2011-12-15
BRPI0921424A2 (pt) 2016-01-05

Similar Documents

Publication Publication Date Title
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
MX2011011960A (es) Peptidos penetradores de celulas.
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
UA98620C2 (uk) Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
PE20100253A1 (es) Mutantes de fgf21
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
RU2009119597A (ru) Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине
JP2010508030A5 (es)
PE20090483A1 (es) Vectores para la expresion multiple de genes
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
PE20110106A1 (es) Peptidos mediadores del eflujo del colesterol mejorados
MY167485A (en) Recombinant human interferon-like proteins
BRPI0607097A2 (pt) peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada
DE602007011616D1 (de) Verfahren zur herstellung von oligopeptiden
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2010057242A3 (de) Vakzin
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
EA201290384A1 (ru) Вирусные цитруллинированные пептиды и их применение
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
WO2009130256A3 (en) Tat protein for preventing or treating aids

Legal Events

Date Code Title Description
FD Application declared void or lapsed